Pulmozyme Access Solutions: What We Do

We would like to welcome you to the Pulmozyme^® Access Solutions website. We are committed to connecting your patients to their medicine, regardless of their ability to pay. We can help you resolve benefits and coverage issues, as well as find co-pay assistance for underinsured patients. We also have programs to provide free medicine for your uninsured patients. At Pulmozyme Access Solutions, we provide you with individualized services to meet your patients' specific needs.

Below are some ways Pulmozyme Access Solutions can help you and your patients with access and reimbursement.

Coverage and Reimbursement
Each year, we help tens of thousands of patients with coverage and reimbursement issues. We have Specialists available who can help your patients connect to the Pulmozyme^® (dornase alfa) Inhalation Solution they need. We can also help you find the right solutions to the coverage and reimbursement issues you might have:

Conducting a benefits investigation
Assisting with a prior authorization for Pulmozyme when this is required by a health plan
Helping with the appeals process when coverage is denied

Patient Assistance
We know the impact on your patients with financial concerns can be significant. Pulmozyme Access Solutions can help. We have several options to help the patient who is uninsured or who has been denied coverage by an insurer. We can also help patients who need help with their co-pays.

For information about our co-pay assistance options, click here
For information about how we can help your uninsured patients, click here

Informational Resources
Pulmozyme Access Solutions provides several services and important information online to help you and your patients on Pulmozyme. These include the following:

Process Flow

The flow chart seen here gives you an overview of how Pulmozyme Access Solutions can work for you.

Pulmozyme (dornase alfa) Inhalation Solution Important Information

Indication and Usage
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.

Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF health care team.

Pulmozyme^® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.